Site Map | Search | Contact    
   SGNA > Resources > Sponsors > Print This Page   


Collaborate

Vendors Forum

Standards & Guidelines

Position Statements

Products & Publications

Gastroenterology Nursing Journal

SGNA News

Awards/Grants

Employment Network

Related Links

Regions

Sponsors

SGNA Speakers Bureau

Continuing Education Approval Units

Minimum Data Set


  Communities

  Online Services
LOGIN


  Events

  Marketplace

  HELP
 


Sponsors

About Procter & Gamble (NYSE:PG)

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Actonel ® , (risedronate sodium) tablets, Asacol ® (mesalamine) delayed-release tablets, Enablex ® (darifenacin) extended-release tablets, Prilosec OTC ® , Metamucil ® , Fibersure ® , Align ® , Pepto-Bismol ® , Vicks ® , PUR ® , Crest ® and Oral-B ® . The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

About Asacol ® (mesalamine) Delayed-Release Tablets 400 mg

Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).

Asacol was well-tolerated in clinical studies. Overall, the incidence of adverse events with Asacol was comparable to placebo. In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35 percent vs. 36 percent), abdominal pain (18 percent vs. 14 percent), eructation (16 percent vs. 15 percent), pain (14 percent vs. eight percent) and nausea (13 percent vs. 15 percent); for the maintenance of remission of UC, the most frequent adverse events were headache (50 percent vs. 50 percent), rhinitis (42 percent vs. 36 percent), diarrhea (35 percent vs. 50 percent), abdominal pain (32 percent vs. 44 percent) and flatulence (24 percent vs. 30 percent). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch , or call 1-800-FDA-1088.

Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol. Please visit http://www.asacol.com/pdf/us-asacol.pdf for full prescribing information.

Home | About | Membership | Education | Resources | Certification

Please feel free to give your opinion on the content, organization, look, and user-friendliness of the SGNA Website.
Click here to send your comments. To view our Privacy Statement, click here.

401 North Michigan Avenue - Chicago, IL 60611-4267
P: 800/245-7462, in Illinois: 312/321-5165 - F: 312/673-6694